Combination of Toripalimab and Chemoradiotherapy in Esophageal Cancer

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Mian XI
Updated on 22 January 2021


Definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable esophageal cancer (EC). However, as high as more than 40% of EC patients experienced locoregional recurrence after concurrent CRT. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. The aim of this study was to evaluate the efficacy and safety of the combination of toripalimab (an anti-PD-1 antibody) combined with definitive CRT in locally advanced esophageal squamous cell carcinoma (ESCC).

Condition Unresectable Esophageal Cancer
Treatment Intensity-modulated radiotherapy, Toripalimab, Paclitaxel/cisplatin
Clinical Study IdentifierNCT04005170
SponsorMian XI
Last Modified on22 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 70 yrs?
Gender: Male or Female
Do you have Unresectable Esophageal Cancer?
Do you have any of these conditions: Do you have Unresectable Esophageal Cancer??
Histologically confirmed squamous cell carcinoma of the esophagus
Absence of hematogenous metastasis disease, confirmed by endoscopic ultrasound (EUS) and PET-CT scan (according to UICC TNM version 8)
Not suitable for surgery (either for medical reasons or patient's choice)
Age at diagnosis 18 to 70 years
No prior cancer therapy
Estimated life expectancy >6 months
Eastern Cooperative Oncology Group performance status 2
No history of concomitant or previous malignancy
The function of important organs meets the following requirements: a. white blood cell count (WBC) 4.0109/L, absolute neutrophil count (ANC) 1.5109/L; b. platelets 100109/L; c. hemoglobin 9g/dL; d. serum albumin 2.8g/dL; e. total bilirubin 1.5ULN, ALT, AST and/or AKP 2.5ULN; f. serum creatinine 1.5ULN or creatinine clearance rate >60 mL/min
Ability to understand the study and sign informed consent

Exclusion Criteria

Patients who have been treated previously with anti-tumor therapy (including chemotherapy, radiotherapy, surgery, immunotherapy, etc.)
Patients with hematogenous metastasis disease at diagnosis
Known or suspected allergy or hypersensitivity to monoclonal antibodies, any ingredients of Toripalimab, and the chemotherapeutic drugs paclitaxel or cisplatin
Patients who have a preexisting or coexisting bleeding disorder
Female patients who are pregnant or lactating
Inability to provide informed consent due to psychological, familial, social and other factors
Presence of CTC grade 3 peripheral neuropathy
A history of malignancies other than esophageal cancer before enrollment, excluding non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer
A history of diabetes for more than 10 years and poorly controlled blood glucose levels
Patients who cannot tolerate chemoradiotherapy due to severe cardiac, lung, liver or kidney dysfunction, or hematopoietic disease or cachexia
Active autoimmune diseases, a history of autoimmune diseases (including but not limited to these diseases or syndromes, such as colitis, hepatitis, hyperthyroidism), a history of immunodeficiency (including a positive HIV test result), or other acquired or congenital immunodeficiency diseases, a history of organ transplantation or allogeneic bone marrow transplantation
A history of interstitial lung disease or non-infectious pneumonia
A history of active pulmonary tuberculosis infection within 1 year or a history of active pulmonary tuberculosis infection more than 1 year ago but without formal anti-tuberculosis treatment
Presence of active hepatitis B (HBV DNA 2000 IU/mL or 104 copies/mL), hepatitis C hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note